Clinical Trial

A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Determine the Safety and Effectiveness of Azeliragon in the Treatment of Patients Hospitalized for Coronavirus Disease 2019 (COVID-19) or Pneumonia

Active, Not Recruiting Phase 2/3
View on ClinicalTrials.gov →
Record status
This record was last updated March 3, 2025 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.
Summary
A new drug called azeliragon could be used to treat patients with COVID-19 or other pneumonia infections but the researchers don't know. In this study, they are learning the effects of azeliragon patients hospitalized for COVID-19 or pneumonia.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-04-13; most recent amendment 2025-02-26.
Status change: Recruiting → Active, Not Recruiting 2025-02-26
Trial Details
NCT Number NCT05815485
Lead Sponsor The University of Texas Medical Branch, Galveston
Conditions COVID-19
Enrollment 144 participants
Start Date 2023-05-04
Primary Completion 2026-04 (estimated)
Study Completion 2026-04 (estimated)
Updated on ClinicalTrials.gov 2025-03-03